RÉSUMÉ
The development of functional neurons is a complex orchestration of multiple signaling pathways controlling cell proliferation and differentiation. Because the balance of antioxidants is important for neuronal survival and development, we hypothesized that ferroptosis must be suppressed to gain neurons. We find that removal of antioxidants diminishes neuronal development and laminar organization of cortical organoids, which is fully restored when ferroptosis is inhibited by ferrostatin-1 or when neuronal differentiation occurs in the presence of vitamin A. Furthermore, iron-overload-induced developmental growth defects in C. elegans are ameliorated by vitamin E and A. We determine that all-trans retinoic acid activates the Retinoic Acid Receptor, which orchestrates the expression of anti-ferroptotic genes. In contrast, retinal and retinol show radical-trapping antioxidant activity. Together, our study reveals an unexpected function of vitamin A in coordinating the expression of essential cellular gatekeepers of ferroptosis, and demonstrates that suppression of ferroptosis by radical-trapping antioxidants or by vitamin A is required to obtain mature neurons and proper laminar organization in cortical organoids.
Sujet(s)
Antioxydants , Caenorhabditis elegans , Ferroptose , Neurones , Rétinol , Animaux , Ferroptose/effets des médicaments et des substances chimiques , Rétinol/pharmacologie , Rétinol/métabolisme , Caenorhabditis elegans/métabolisme , Caenorhabditis elegans/effets des médicaments et des substances chimiques , Antioxydants/pharmacologie , Neurones/métabolisme , Neurones/effets des médicaments et des substances chimiques , Neurones/cytologie , Cyclohexylamines/pharmacologie , Différenciation cellulaire/effets des médicaments et des substances chimiques , Vitamine E/pharmacologie , Récepteurs à l'acide rétinoïque/métabolisme , Récepteurs à l'acide rétinoïque/génétique , Trétinoïne/pharmacologie , Organoïdes/effets des médicaments et des substances chimiques , Organoïdes/métabolisme , Neurogenèse/effets des médicaments et des substances chimiques , Souris , Humains , Protéines de Caenorhabditis elegans/métabolisme , Protéines de Caenorhabditis elegans/génétique , Transduction du signal/effets des médicaments et des substances chimiques , PhénylènediaminesRÉSUMÉ
The aim of this study was to investigate the possible protective effects of apelin, which is known to have antioxidant and anti-inflammatory effects, on changes in neurogenesis in newborns of pregnant rats with L-NAME-induced preeclampsia. Wistar albino female rats were divided into four experimental groups: Control, Apelin, Preeclampsia and Preeclampsia + Apelin. Blood pressure was measured on the 5th, 11th and 17th days of gestation, urine protein was analyzed from urine samples collected for 24 h on the 6th, 12th and 18th days and serum creatinine was analyzed from serum samples. Maternal kidney and placenta tissues were obtained to establish the preeclampsia model, and neonatal brain tissues including the cortex, hippocampus and cerebellum regions were obtained to investigate neurogenesis and examined by histological and immunohistochemical methods. The number of newborns, body weight and brain weight of the newborns were measured. eNOS, IL-10, nNOS and NO levels in the brain analyzed via ELISA. Mean arterial pressure, urine protein and serum creatinine increased in the preeclampsia. Newborn weight decreased in the Preeclampsia group, the values in the Preeclampsia + Apelin group were closer to the Control and Apelin groups. In the Preeclampsia group, edema and dilatation in the proximal and distal tubules of kidneys, perivillous fibrin deposition and increase in syncytial nodules of placenta were observed. VEGF immunoreactivity decreased and iNOS immunoreactivity increased in both kidney and placenta. In neonatal brain tissue examinations, cytotoxic edema accompanied by thinning of cortex, delayed migration and lower cell counts in the hippocampus, and increase in intercellular spaces and EGL thickening in the cerebellum were observed in the preeclampsia. Expression of NeuN, GFAP, MBP, IL-10, eNOS, nNOS and NO levels decreased, whereas expression of Iba-1 increased in the preeclampsia. In the Preeclampsia + Apelin group, these findings were similar to the Control and Apelin groups. Apelin administration was found to be beneficial for preventing the adverse consequences of preeclampsia, but further experimental and clinical studies are needed to better understand these effects.
Sujet(s)
Animaux nouveau-nés , Apeline , Encéphale , L-NAME , Neurogenèse , Pré-éclampsie , Rat Wistar , Femelle , Grossesse , Pré-éclampsie/induit chimiquement , Pré-éclampsie/métabolisme , Animaux , Apeline/métabolisme , Neurogenèse/effets des médicaments et des substances chimiques , Rats , Encéphale/métabolisme , Encéphale/anatomopathologie , Encéphale/effets des médicaments et des substances chimiques , L-NAME/pharmacologie , Placenta/métabolisme , Modèles animaux de maladie humaine , Nitric oxide synthase type III/métabolisme , Monoxyde d'azote/métabolisme , Interleukine-10/métabolisme , Interleukine-10/sang , Nitric oxide synthase type I/métabolismeRÉSUMÉ
BACKGROUND: Salidroside is the major bioactive and pharmacological active substance in Rhodiola rosea L. It has been reported to have neuroprotective effects on cerebral ischemia/reperfusion (I/R). However, whether salidroside can enhance neural regeneration after cerebral I/R is still unknown. This study investigated the effects of salidroside on the endogenous neural regeneration after cerebral I/R and the related mechanism. METHODS: Focal cerebral I/R was induced in rats by transient middle cerebral artery occlusion/reperfusion (MCAO/R). The rats were intraperitoneally treated salidroside once daily for 7 consecutive days. Neurobehavioral assessments were performed at 3 days and 7 days after the injury. TTC staining was performed to assess cerebral infarct volume. To evaluate the survival of neurons, immunohistochemical staining of Neuronal Nuclei (NeuN) in the ischemic hemisphere were conducted. Also, immunofluorescence double or triple staining of the biomarkers of proliferating neural progenitor cells in Subventricular Zone (SVZ) and striatum of the ischemia hemisphere were performed to investigate the neurogenesis. Furthermore, reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) were used to detect the expression of neurotrophic factors (NTFs) brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Expression of Notch1 and its target molecular Hes1 were also analyzed by western-blotting and RT-PCR. RESULTS: Salidroside treatment ameliorated I/R induced neurobehavioral impairment, and reduced infarct volume. Salidroside also restored NeuN positive cells loss after I/R injury. Cerebral I/R injury significantly increased the expression of 5-Bromo-2'-Deoxyuridine (BrdU) and doublecotin (DCX), elevated the number of BrdU/Nestin/DCX triple-labeled cells in SVZ, and BrdU/Nestin/glial fibrillary acidic protein (GFAP) triple-labeled cells in striatum. Salidroside treatment further promoted the proliferation of BrdU/DCX labeled neuroblasts and BrdU/Nestin/GFAP labeled reactive astrocytes. Furthermore, salidroside elevated the mRNA expression and protein concentration of BDNF and NGF in ischemia periphery area, as well. Mechanistically, salidroside elevated Notch1/Hes1 mRNA expression in SVZ. The protein levels of them were also increased after salidroside administration. CONCLUSIONS: Salidroside enhances the endogenous neural regeneration after cerebral I/R. The mechanism of the effect may involve the regulation of BDNF/NGF and Notch signaling pathway.
Sujet(s)
Encéphalopathie ischémique , Glucosides , Régénération nerveuse , Phénols , Rat Sprague-Dawley , Lésion d'ischémie-reperfusion , Transduction du signal , Animaux , Glucosides/pharmacologie , Phénols/pharmacologie , Rats , Mâle , Transduction du signal/effets des médicaments et des substances chimiques , Lésion d'ischémie-reperfusion/traitement médicamenteux , Encéphalopathie ischémique/traitement médicamenteux , Régénération nerveuse/effets des médicaments et des substances chimiques , Neuroprotecteurs/pharmacologie , Facteurs de croissance nerveuse/métabolisme , Modèles animaux de maladie humaine , Récepteurs Notch/métabolisme , Infarctus du territoire de l'artère cérébrale moyenne/traitement médicamenteux , Neurogenèse/effets des médicaments et des substances chimiquesRÉSUMÉ
BACKGROUND: Chronic Gulf War Illness (GWI) is characterized by cognitive and mood impairments, as well as persistent neuroinflammation and oxidative stress. This study aimed to investigate the efficacy of Epidiolex®, a Food and Drug Administration (FDA)-approved cannabidiol (CBD), in improving brain function in a rat model of chronic GWI. METHODS: Six months after exposure to low doses of GWI-related chemicals [pyridostigmine bromide, N,N-diethyl-meta-toluamide (DEET), and permethrin (PER)] along with moderate stress, rats with chronic GWI were administered either vehicle (VEH) or CBD (20 mg/kg, oral) for 16 weeks. Neurobehavioral tests were conducted on 11 weeks after treatment initiation to evaluate the performance of rats in tasks related to associative recognition memory, object location memory, pattern separation, and sucrose preference. The effect of CBD on hyperalgesia was also examined. The brain tissues were processed for immunohistochemical and molecular studies following behavioral tests. RESULTS: GWI rats treated with VEH exhibited impairments in all cognitive tasks and anhedonia, whereas CBD-treated GWI rats showed improvements in all cognitive tasks and no anhedonia. Additionally, CBD treatment alleviated hyperalgesia in GWI rats. Analysis of hippocampal tissues from VEH-treated rats revealed astrocyte hypertrophy and increased percentages of activated microglia presenting NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) complexes as well as elevated levels of proteins involved in NLRP3 inflammasome activation and Janus kinase/signal transducers and activators of the transcription (JAK/STAT) signaling. Furthermore, there were increased concentrations of proinflammatory and oxidative stress markers along with decreased neurogenesis. In contrast, the hippocampus from CBD-treated GWI rats displayed reduced levels of proteins mediating the activation of NLRP3 inflammasomes and JAK/STAT signaling, normalized concentrations of proinflammatory cytokines and oxidative stress markers, and improved neurogenesis. Notably, CBD treatment did not alter the concentration of endogenous cannabinoid anandamide in the hippocampus. CONCLUSIONS: The use of an FDA-approved CBD (Epidiolex®) has been shown to effectively alleviate cognitive and mood impairments as well as hyperalgesia associated with chronic GWI. Importantly, the improvements observed in rats with chronic GWI in this study were attributed to the ability of CBD to significantly suppress signaling pathways that perpetuate chronic neuroinflammation.
Sujet(s)
Cannabidiol , Dysfonctionnement cognitif , Hyperalgésie , Neurogenèse , Maladies neuro-inflammatoires , Syndrome de la guerre du Golfe , Animaux , Cannabidiol/pharmacologie , Cannabidiol/usage thérapeutique , Rats , Syndrome de la guerre du Golfe/traitement médicamenteux , Syndrome de la guerre du Golfe/complications , Mâle , Hyperalgésie/traitement médicamenteux , Maladies neuro-inflammatoires/traitement médicamenteux , Dysfonctionnement cognitif/traitement médicamenteux , Dysfonctionnement cognitif/étiologie , Neurogenèse/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Rat Sprague-Dawley , Transduction du signal/effets des médicaments et des substances chimiques , Troubles de l'humeur/traitement médicamenteux , Stress oxydatif/effets des médicaments et des substances chimiques , Hippocampe/effets des médicaments et des substances chimiques , Bromure de pyridostigmine/pharmacologie , Bromure de pyridostigmine/usage thérapeutiqueRÉSUMÉ
Autism spectrum disorder (ASD) is a multifactorial neurodevelopmental condition with several identified risk factors, both genetic and non-genetic. Among these, prenatal exposure to valproic acid (VPA) has been extensively associated with the development of the disorder. The zebrafish, a cost- and time-effective model, is useful for studying ASD features. Using validated VPA-induced ASD zebrafish models, we aimed to provide new insights into VPA exposure effects during embryonic development and to identify new potential biomarkers associated with ASD-like features. Dose-response analyses were performed in vivo to study larval phenotypes and mechanisms underlying neuroinflammation, mitochondrial dysfunction, oxidative stress, microglial cell status, and motor behaviour. Wild-type and transgenic Tg(mpeg1:EGFP) zebrafish were water-exposed to VPA doses (5 to 500 µM) from 6 to 120 h post-fertilisation (hpf). Embryos and larvae were monitored daily to assess survival and hatching rates, and numerous analyses and tests were conducted from 24 to 120 hpf. VPA doses higher than 50 µM worsened survival and hatching rates, while doses of 25 µM or more altered morphology, microglial status, and larval behaviours. VPA 50 µM also affected mRNA expression of inflammatory cytokines and neurogenesis-related genes, mitochondrial respiration, and reactive oxygen species accumulation. The study confirmed that VPA alters brain homeostasis, synaptic interconnections, and neurogenesis-related signalling pathways, contributing to ASD aetiopathogenesis. Further studies are essential to identify novel ASD biomarkers for developing new drug targets and tailored therapeutic interventions for ASD.
Sujet(s)
Trouble du spectre autistique , Modèles animaux de maladie humaine , Acide valproïque , Danio zébré , Animaux , Acide valproïque/pharmacologie , Acide valproïque/effets indésirables , Trouble du spectre autistique/induit chimiquement , Trouble du spectre autistique/génétique , Trouble du spectre autistique/anatomopathologie , Larve/effets des médicaments et des substances chimiques , Animal génétiquement modifié , Stress oxydatif/effets des médicaments et des substances chimiques , Mitochondries/effets des médicaments et des substances chimiques , Mitochondries/métabolisme , Microglie/effets des médicaments et des substances chimiques , Microglie/anatomopathologie , Microglie/métabolisme , Encéphale/effets des médicaments et des substances chimiques , Encéphale/anatomopathologie , Encéphale/métabolisme , Embryon non mammalien/effets des médicaments et des substances chimiques , Embryon non mammalien/métabolisme , Neurogenèse/effets des médicaments et des substances chimiquesRÉSUMÉ
Benzo[a]pyrene (B[a]P) is known to inhibit neurodifferentiation and induce neurodegeneration. Agarwood or Aquilaria crassna (AC), a plant with health-promoting properties, may counteract the neurotoxic effects of B[a]P by promoting neuronal growth and survival. This study investigated the protective effect of AC leaf ethanolic extract (ACEE) on the B[a]P-induced impairment of neuronal differentiation. A transcriptomic analysis identified the canonical pathway, the biological network, and the differentially expressed genes (DEGs) that are changed in response to neuronal differentiation and neurogenesis. Several genes, including CXCR4, ENPP2, GAP43, GFRA2, NELL2, NFASC, NSG2, NGB, BASP1, and NEUROD1, in B[a]P-treated SH-SY5Y cells were up-regulated after treatment with ACEE. Notably, a Western blot analysis further confirmed that ACEE increased the protein levels of GAP43 and neuroglobin. B[a]P treatment led to decreased phosphorylation of Akt and increased phosphorylation of ERK in SH-SY5Y cells; however, ACEE was able to reverse these effects. Clionasterol and lupenone were identified in ACEE. Molecular docking showed that these two phytochemicals had significant interactions with CXCR4, GDNF family receptor alpha (GFRA), and retinoid X receptors (RXRs). In conclusion, ACEE may be a potential alternative medicine for the prevention of impaired neuronal differentiation and neurodegenerative diseases.
Sujet(s)
Benzo[a]pyrène , Neuroprotecteurs , Extraits de plantes , Thymelaeaceae , Humains , Extraits de plantes/pharmacologie , Neuroprotecteurs/pharmacologie , Benzo[a]pyrène/toxicité , Lignée cellulaire tumorale , Thymelaeaceae/composition chimique , Analyse de profil d'expression de gènes , RNA-Seq , Feuilles de plante/composition chimique , Neurones/effets des médicaments et des substances chimiques , Neurones/métabolisme , Transcriptome/effets des médicaments et des substances chimiques , Différenciation cellulaire/effets des médicaments et des substances chimiques , Neurogenèse/effets des médicaments et des substances chimiques , Simulation de docking moléculaire , Survie cellulaire/effets des médicaments et des substances chimiquesRÉSUMÉ
The Ribosomal S6 Kinase (RSK) family of serine/threonine kinases function as key downstream effectors of the MAPK signaling cascade. In the nervous system, RSK signaling plays crucial roles in neuronal development and contributes to activity-dependent neuronal plasticity. This study examined the role of RSK signaling in cell viability during neuronal development and in neuroprotection in the mature nervous system. Using neuronal cell-culture-based profiling, we found that suppressing RSK signaling led to significant cell death in developing primary neuronal cultures. To this end, treatment with the RSK inhibitors BiD1870 or SL0101 on the first day of culturing resulted in over 80% cell death. In contrast, more mature cultures showed attenuated cell death upon RSK inhibition. Inhibition of RSK signaling during early neuronal development also disrupted neurite outgrowth and cell growth. In maturing hippocampal explant cultures, treatment with BiD1870 had minimal effects on cell viability, but led to a striking augmentation of NMDA-induced cell death. Finally, we used the endothelin 1 (ET-1) model of ischemia to examine the neuroprotective effects of RSK signaling in the mature hippocampus in vivo. Notably, in the absence of RSK inhibition, the granule cell layer (GCL) was resistant to the effects of ET-1; However, disruption of RSK signaling (via the microinjection of BiD1870) prior to ET-1 injection triggered cell death within the GCL, thus indicating a neuroprotective role for RSK signaling in the mature nervous system. Together these data reveal distinct, developmentally-defined, roles for RSK signaling in the nervous system.
Sujet(s)
Mort cellulaire , Survie cellulaire , Neurones , Ribosomal Protein S6 Kinases , Transduction du signal , Animaux , Neurones/effets des médicaments et des substances chimiques , Neurones/métabolisme , Mort cellulaire/effets des médicaments et des substances chimiques , Mort cellulaire/physiologie , Survie cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/physiologie , Ribosomal Protein S6 Kinases/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Transduction du signal/physiologie , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Cellules cultivées , Endothéline-1/pharmacologie , Endothéline-1/métabolisme , N-Méthyl-aspartate/pharmacologie , Rat Sprague-Dawley , Rats , Neurogenèse/physiologie , Neurogenèse/effets des médicaments et des substances chimiques , PtéridinesRÉSUMÉ
5-Methoxy-3-(5-methoxyindolin-2-yl)-1H-indole (3), whose structure was unambiguously elucidated by X-ray analysis, was identified as a multi-target compound with potential application in neurodegenerative diseases. It is a low nanomolar inhibitor of QR2 (IC50 = 7.7 nM), with greater potency than melatonin and comparable efficacy to the most potent QR2 inhibitors described to date. Molecular docking studies revealed the potential binding mode of 3 to QR2, which explains its superior potency compared to melatonin. Furthermore, compound 3 inhibits hMAO-A, hMAO-B and hLOX-5 in the low micromolar range and is an excellent ROS scavenger. In phenotypic assays, compound 3 showed neuroprotective activity in a cellular model of oxidative stress damage, it was non-toxic, and was able to activate neurogenesis from neural stem-cell niches of adult mice. These excellent biological properties, together with its both good in silico and in vitro drug-like profile, highlight compound 3 as a promising drug candidate for neurodegenerative diseases.
Sujet(s)
Mélatonine , Simulation de docking moléculaire , Neurogenèse , Neuroprotecteurs , Neuroprotecteurs/pharmacologie , Neuroprotecteurs/composition chimique , Neuroprotecteurs/synthèse chimique , Mélatonine/pharmacologie , Mélatonine/composition chimique , Animaux , Souris , Humains , Relation structure-activité , Neurogenèse/effets des médicaments et des substances chimiques , Structure moléculaire , Découverte de médicament , Quinone reductases/antagonistes et inhibiteurs , Quinone reductases/métabolisme , Antienzymes/pharmacologie , Antienzymes/composition chimique , Antienzymes/synthèse chimique , Relation dose-effet des médicamentsRÉSUMÉ
BACKGROUND: Neural stem cell (NSC) proliferation and differentiation in the mammalian brain decreases to minimal levels postnatally. Nevertheless, neurogenic niches persist in the adult cortex and hippocampus in rodents, primates and humans, with adult NSC differentiation sharing key regulatory mechanisms with development. Adult neurogenesis impairments have been linked to Alzheimer's disease (AD) pathology. Addressing these impairments by using neurotrophic factors is a promising new avenue for therapeutic intervention based on neurogenesis. However, this possibility has been hindered by technical difficulties of using in-vivo models to conduct screens, including working with scarce NSCs in the adult brain and differences between human and mouse models or ethical limitations. METHODS: Here, we use a combination of mouse and human stem cell models for comprehensive in-vitro characterization of a novel neurogenic compound, focusing on the brain-derived neurotrophic factor (BDNF) pathway. The ability of ENT-A011, a steroidal dehydroepiandrosterone derivative, to activate the tyrosine receptor kinase B (TrkB) receptor was tested through western blotting in NIH-3T3 cells and its neurogenic and neuroprotective action were assessed through proliferation, cell death and Amyloid-ß (Aß) toxicity assays in mouse primary adult hippocampal NSCs, mouse embryonic cortical NSCs and neural progenitor cells (NPCs) differentiated from three human induced pluripotent stem cell lines from healthy and AD donors. RNA-seq profiling was used to assess if the compound acts through the same gene network as BDNF in human NPCs. RESULTS: ENT-A011 was able to increase proliferation of mouse primary adult hippocampal NSCs and embryonic cortical NSCs, in the absence of EGF/FGF, while reducing Aß-induced cell death, acting selectively through TrkB activation. The compound was able to increase astrocytic gene markers involved in NSC maintenance, protect hippocampal neurons from Αß toxicity and prevent synapse loss after Aß treatment. ENT-A011 successfully induces proliferation and prevents cell death after Aß toxicity in human NPCs, acting through a core gene network shared with BDNF as shown through RNA-seq. CONCLUSIONS: Our work characterizes a novel BDNF mimetic with preferable pharmacological properties and neurogenic and neuroprotective actions in Alzheimer's disease via stem cell-based screening, demonstrating the promise of stem cell systems for short-listing competitive candidates for further testing.
Sujet(s)
Maladie d'Alzheimer , Cellules souches neurales , Neurogenèse , Neuroprotecteurs , Récepteur trkB , Animaux , Humains , Maladie d'Alzheimer/traitement médicamenteux , Maladie d'Alzheimer/métabolisme , Maladie d'Alzheimer/anatomopathologie , Souris , Neurogenèse/effets des médicaments et des substances chimiques , Récepteur trkB/métabolisme , Récepteur trkB/agonistes , Récepteur trkB/génétique , Cellules souches neurales/effets des médicaments et des substances chimiques , Cellules souches neurales/métabolisme , Cellules souches neurales/cytologie , Neuroprotecteurs/pharmacologie , Facteur neurotrophique dérivé du cerveau/métabolisme , Facteur neurotrophique dérivé du cerveau/génétique , Différenciation cellulaire/effets des médicaments et des substances chimiques , Prolifération cellulaire/effets des médicaments et des substances chimiques , Peptides bêta-amyloïdes/métabolisme , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolismeRÉSUMÉ
In the intricate landscape of Traumatic Brain Injury (TBI), the management of TBI remains a challenging task due to the extremely complex pathophysiological conditions and excessive release of reactive oxygen species (ROS) at the injury site and the limited regenerative capacities of the central nervous system (CNS). Existing pharmaceutical interventions are limited in their ability to efficiently cross the blood-brain barrier (BBB) and expeditiously target areas of brain inflammation. In response to these challenges herein, we designed novel mussel inspired polydopamine (PDA)-coated mesoporous silica nanoparticles (PDA-AMSNs) with excellent antioxidative ability to deliver a new potential therapeutic GSK-3ß inhibitor lead small molecule abbreviated as Neuro Chemical Modulator (NCM) at the TBI site using a neuroprotective peptide hydrogel (PANAP). PDA-AMSNs loaded with NCM (i.e., PDA-AMSN-D) into the matrix of PANAP were injected into the damaged area in an in vivo cryogenic brain injury model (CBI). This approach is specifically built while keeping the logic AND gate circuit as the primary focus. Where NCM and PDA-AMSNs act as two input signals and neurological functional recovery as a single output. Therapeutically, PDA-AMSN-D significantly decreased infarct volume, enhanced neurogenesis, rejuvenated BBB senescence, and accelerated neurological function recovery in a CBI.
Sujet(s)
Antioxydants , Bivalvia , Lésions traumatiques de l'encéphale , Indoles , Nanocomposites , Neurogenèse , Stress oxydatif , Polymères , Indoles/composition chimique , Indoles/pharmacologie , Lésions traumatiques de l'encéphale/traitement médicamenteux , Lésions traumatiques de l'encéphale/anatomopathologie , Lésions traumatiques de l'encéphale/métabolisme , Polymères/composition chimique , Polymères/pharmacologie , Animaux , Stress oxydatif/effets des médicaments et des substances chimiques , Antioxydants/composition chimique , Antioxydants/pharmacologie , Nanocomposites/composition chimique , Bivalvia/composition chimique , Neurogenèse/effets des médicaments et des substances chimiques , Neuroprotecteurs/composition chimique , Neuroprotecteurs/pharmacologie , Silice/composition chimique , Barrière hémato-encéphalique/effets des médicaments et des substances chimiques , Barrière hémato-encéphalique/métabolisme , MâleRÉSUMÉ
Cocoa is widely known for its health benefits, but its neurocognitive impact remains underexplored. This preclinical study aimed to investigate the effects of cocoa and cocoa polyphenols on hippocampal neuroplasticity, cognitive function and emotional behavior. Seventy young-adult C57BL/6JRj male and female mice were fed either a standard diet (CTR) or a diet enriched with 10% high-phenolic content cocoa (HPC) or low-phenolic content cocoa (LPC) for at least four weeks. In a first experiment, behavioral tests assessing exploratory behavior, emotional responses and hippocampal-dependent memory were conducted four weeks into the diet, followed by animal sacrifice a week later. Adult hippocampal neurogenesis and brain-derived neurotrophic factor (BDNF) expression in the hippocampus and prefrontal cortex were evaluated using immunohistochemistry and western blot. In a different experiment, hippocampal synaptic response, long-term potentiation and presynaptic-dependent short-term plasticity were studied by electrophysiology. Cocoa-enriched diets had minimal effects on exploratory activity and anxiety-like behavior, except for reduced locomotion in the LPC group. Only the HPC diet enhanced object recognition memory, while place recognition memory and spatial navigation remained unaffected. The HPC diet also increased adult hippocampal neurogenesis, boosting the proliferation, survival and number of young adult-born neurons. However, both cocoa-enriched diets increased immobility in the forced swimming test and hippocampal BDNF expression. Hippocampal electrophysiology revealed no alterations in neuroplasticity among diets. The results were mostly unaffected by sex. Overall, the HPC diet demonstrated greater potential regarding cognitive and neuroplastic benefits, suggesting a key role of cocoa flavanols in dietary interventions aimed at enhancing brain health.
Sujet(s)
Facteur neurotrophique dérivé du cerveau , Cacaoyer , Hippocampe , Mémoire , Souris de lignée C57BL , Neurogenèse , Animaux , Facteur neurotrophique dérivé du cerveau/métabolisme , Facteur neurotrophique dérivé du cerveau/génétique , Neurogenèse/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Hippocampe/effets des médicaments et des substances chimiques , Souris , Mâle , Femelle , Mémoire/effets des médicaments et des substances chimiques , Cacaoyer/composition chimique , Plasticité neuronale/effets des médicaments et des substances chimiques , Régime alimentaireRÉSUMÉ
Critical-size bone defect repair presents multiple challenges, such as osteogenesis, vascularization, and neurogenesis. Current biomaterials for bone repair need more consideration for the above functions. Organic-inorganic composites combined with bioactive ions offer significant advantages in bone regeneration. In our work, we prepared an organic-inorganic composite material by blending polylactic acid (PLA) with 3-aminopropyltriethoxysilane (APTES)-modified magnesium silicate (A-M2S) and fabricated it by 3D printing. With the increase of A-M2S proportion, the hydrophilicity and mineralization ability showed an enhanced trend, and the compressive strength and elastic modulus were increased from 15.29 MPa and 94.61 MPa to 44.30 MPa and 435.77 MPa, respectively. Furthermore, A-M2S/PLA scaffolds not only exhibited good cytocompatibility of bone marrow mesenchymal stem cells (BMSCs), human umbilical vein endothelial cells (HUVECs), and Schwann cells (SCs), but also effectively promoted osteogenesis, angiogenesis, and neurogenesis in vitro. After implanting 10% A-M2S/PLA scaffolds in vivo, the scaffolds showed the most effective repair of cranium defects compared to the blank and control group (PLA). Additionally, they promoted the secretion of proteins related to bone regeneration and neurovascular formation. These results provided the basis for expanding the application of A-M2S and PLA in bone tissue engineering and presented a novel concept for neurovascularized bone repair.
Sujet(s)
Régénération osseuse , Cellules endothéliales de la veine ombilicale humaine , Silicates de magnésium , Cellules souches mésenchymateuses , Ostéogenèse , Polyesters , Impression tridimensionnelle , Structures d'échafaudage tissulaires , Régénération osseuse/effets des médicaments et des substances chimiques , Structures d'échafaudage tissulaires/composition chimique , Polyesters/composition chimique , Humains , Cellules endothéliales de la veine ombilicale humaine/effets des médicaments et des substances chimiques , Cellules souches mésenchymateuses/effets des médicaments et des substances chimiques , Cellules souches mésenchymateuses/cytologie , Ostéogenèse/effets des médicaments et des substances chimiques , Animaux , Silicates de magnésium/composition chimique , Ingénierie tissulaire/méthodes , Matériaux biocompatibles/composition chimique , Matériaux biocompatibles/pharmacologie , Cellules de Schwann/effets des médicaments et des substances chimiques , Cellules de Schwann/cytologie , Silanes/composition chimique , Silanes/pharmacologie , Neurogenèse/effets des médicaments et des substances chimiques , Propylamines/composition chimique , Propylamines/pharmacologie , Néovascularisation physiologique/effets des médicaments et des substances chimiquesRÉSUMÉ
OBJECTIVE: To investigate the effects of luteolin on chronic unpredictable mild stress (CUMS)-induced depressive rats and corticosterone (CORT)-induced depressive primary hippocampal neurons, and to elucidate the mechanism behind the action. METHODS: The antidepressant mechanism of luteolin was studied by using CUMS rat model and primary hippocampal neurons in fetal rats. In vivo, novelty suppressed feeding, open-field and sucrose preference tests as well as Morris water maze were evaluated. The content of brain derived neurotrophic factor (BDNF), 5-hydroxytryptamine (5-HT), norepinephrine (NE), and dopamine (DA) in serum were detected by enzyme-linked immunosorbent assay. The mechanisms of luteolin were explored based on neurotrophin and hippocampal neurogenesis, and proliferation. Survival of the septo-temporal axis in hippocampus was assayed using the 5-bromo-2-deoxyuridine (BrdU), the expression of BDNF, neurotrophin-3 (NT-3), and nerve growth factor (NGF) in hippocampus dentate gyrus region were measured by Western-blotting. In vitro, BDNF, NT-3, tropomyosin receptor kinase B (TrkB), and phosphorylated cyclic adenosine monophosphate responsive element binding protein (p-CREB) were detected through the high content analysis (HCA) to investigate neurotrophin and apoptosis. RESULTS: Induction of CUMS in rats induced depressive symptoms, while luteolin significantly enhanced sucrose consumption, decreased feeding latency, increased locomotor activity, escape latency, distance of target quadrant and regulated the content of depressive-like biomarkers. Histology analysis revealed that luteolin increased the abundance of new born neurons that had been labeled with BrdU, BrdU + neuronal nuclear antigen, and BrdU + doublecortin in septo-temporal axis of S2 (mid-septal) and T3 (mid-temporal). Moreover, expression of BDNF, NT-3, and NGF increased significantly in the septo-temporal axis of S2 and T3. HCA showed increased expression of BDNF, NT-3, TrkB and p-CREB in primary hippocampal neurons. CONCLUSION: The results provided direct evidence that luteolin has an antidepressant effect and could effectively promote the regeneration of the septotemporal axis nerve and hippocampal neuronutrition, which suggested that the antidepressant effect of luteolin may be related to hippocampal neurogenesis.
Sujet(s)
Facteur neurotrophique dérivé du cerveau , Hippocampe , Lutéoline , Neurogenèse , Neurones , Rat Sprague-Dawley , Animaux , Lutéoline/pharmacologie , Rats , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Neurogenèse/effets des médicaments et des substances chimiques , Mâle , Facteur neurotrophique dérivé du cerveau/métabolisme , Facteur neurotrophique dérivé du cerveau/génétique , Neurones/effets des médicaments et des substances chimiques , Neurones/métabolisme , Humains , Stress psychologique/physiopathologie , Stress psychologique/traitement médicamenteux , Femelle , Dépression/traitement médicamenteux , Dépression/métabolisme , Dépression/physiopathologie , Antidépresseurs/pharmacologie , Neurotrophine-3/métabolisme , Neurotrophine-3/génétiqueRÉSUMÉ
Hippocampal seizures mimicking mesial temporal lobe epilepsy cause a profound disruption of the adult neurogenic niche in mice. Seizures provoke neural stem cells to switch to a reactive phenotype (reactive neural stem cells, React-NSCs) characterized by multibranched hypertrophic morphology, massive activation to enter mitosis, symmetric division, and final differentiation into reactive astrocytes. As a result, neurogenesis is chronically impaired. Here, using a mouse model of mesial temporal lobe epilepsy, we show that the epidermal growth factor receptor (EGFR) signaling pathway is key for the induction of React-NSCs and that its inhibition exerts a beneficial effect on the neurogenic niche. We show that during the initial days after the induction of seizures by a single intrahippocampal injection of kainic acid, a strong release of zinc and heparin-binding epidermal growth factor, both activators of the EGFR signaling pathway in neural stem cells, is produced. Administration of the EGFR inhibitor gefitinib, a chemotherapeutic in clinical phase IV, prevents the induction of React-NSCs and preserves neurogenesis.
Sujet(s)
Récepteurs ErbB , Facteur de croissance de type EGF liant l'héparine , Hippocampe , Cellules souches neurales , Neurogenèse , Crises épileptiques , Transduction du signal , Animaux , Récepteurs ErbB/métabolisme , Cellules souches neurales/métabolisme , Cellules souches neurales/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Souris , Facteur de croissance de type EGF liant l'héparine/métabolisme , Crises épileptiques/métabolisme , Neurogenèse/effets des médicaments et des substances chimiques , Transduction du signal/effets des médicaments et des substances chimiques , Mâle , Modèles animaux de maladie humaine , Géfitinib/pharmacologie , Épilepsie temporale/métabolisme , Différenciation cellulaire/effets des médicaments et des substances chimiques , Acide kaïnique/pharmacologie , Souris de lignée C57BLRÉSUMÉ
Regulation of physiological homeostasis, including energy balance, is thought to be modified by low levels of adult neurogenesis in the hypothalamus. Hormones such as oestradiol can influence both embryonic and adult hypothalamic neurogenic programs, demonstrating a sensitivity of hypothalamic neural progenitor cells to endogenous hormones. Previously we showed that gestational exposure to environmental levels of the xenoestrogen bisphenol A (BPA) changed neural progenitor cell behaviors in the embryo; however, we did not examine if these changes were permanent to affect adult neurogenesis. Here we investigated whether adult neuro- and/or gliogenesis were altered in mice prenatally exposed to BPA and placed on a high-fat diet challenge. Gestationally exposed adult female mice on a standard diet gained less weight than non-BPA controls, whereas gestationally exposed BPA females on a high-fat diet gained more weight than controls. Males exposed to gestational BPA showed no differences in weight gain relative to control males. Concomitantly, adult neurogenesis was increased in the VMH, DMH, and PVN of adult female mice exposed to BPA on standard diet, suggesting that disrupted adult neurogenesis might perturb normal energy balance regulation in females. These results add to growing evidence that low-dose BPA exposure in utero causes changes to adult hypothalamic function.
Sujet(s)
Composés benzhydryliques , Métabolisme énergétique , Homéostasie , Hypothalamus , Neurogenèse , Phénols , Effets différés de l'exposition prénatale à des facteurs de risque , Animaux , Composés benzhydryliques/toxicité , Femelle , Phénols/toxicité , Neurogenèse/effets des médicaments et des substances chimiques , Grossesse , Souris , Hypothalamus/effets des médicaments et des substances chimiques , Hypothalamus/métabolisme , Effets différés de l'exposition prénatale à des facteurs de risque/induit chimiquement , Homéostasie/effets des médicaments et des substances chimiques , Métabolisme énergétique/effets des médicaments et des substances chimiques , Mâle , Alimentation riche en graisse/effets indésirablesRÉSUMÉ
Schizophrenia impacts about 1 % of the global population, with clozapine (CLZ) being a critical treatment for refractory cases despite its limitations in effectiveness and adverse effects. Therefore, the search for more effective treatments remains urgent. Light treatment (LT) recognized for enhancing cognition and mood, presents a promising complementary approach. This study investigated the effects of CLZ and LT on cognitive impairments in a sub-chronic MK-801 induced schizophrenia mouse model. Results showed that both CLZ and CLZ + LT treatment elevate cognitive performance of sub-chronic MK-801 treated mice in serial behavioral tests over two months. Histological analysis revealed increased dendritic spine density and branching, and synaptic repair in the hippocampus with CLZ and CLZ + LT interventions. Furthermore, both treatments increased brain-derived neurotrophic factor (BDNF) expression in the hippocampus, likely contributing to cognitive amelioration in MK-801 treated mice. Additionally, BrdU labeling revealed that CLZ + LT further enhances neurogenesis in the dentate gyrus (DG) and lateral ventricle (LV) of sub-chronic MK-801 treated mice. These findings may have implications for the development of noninvasive and adjunctive treatment strategies aimed at alleviating cognitive impairments and improving functional outcomes in individuals with schizophrenia.
Sujet(s)
Neuroleptiques , Clozapine , Dysfonctionnement cognitif , Maléate de dizocilpine , Hippocampe , Neurogenèse , Plasticité neuronale , Schizophrénie , Animaux , Clozapine/pharmacologie , Maléate de dizocilpine/pharmacologie , Souris , Neurogenèse/effets des médicaments et des substances chimiques , Mâle , Dysfonctionnement cognitif/traitement médicamenteux , Schizophrénie/traitement médicamenteux , Plasticité neuronale/effets des médicaments et des substances chimiques , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Neuroleptiques/pharmacologie , Facteur neurotrophique dérivé du cerveau/métabolisme , Modèles animaux de maladie humaine , Souris de lignée C57BL , Lumière , Association thérapeutiqueRÉSUMÉ
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by cognitive decline and memory loss. Imipramine, a tricyclic antidepressant, has potent anti-inflammatory and antioxidant properties in the central nervous system. The aim of this study was to investigate the neuroprotective effects of imipramine on streptozotocin (STZ)-induced memory impairment. Male Wistar rats received an intracerebroventricular injection of STZ (3 mg/kg, 3 µl/ventricle) using the stereotaxic apparatus. The Morris water maze and passive avoidance tests were used to evaluate cognitive functions. 24 h after the STZ injection, imipramine was administered intraperitoneally at doses of 10 or 20 mg/kg for 14 consecutive days. The mRNA and protein levels of neurotrophic factors (BDNF and GDNF) and pro-inflammatory cytokines (IL-6, IL-1ß, and TNF-α) were measured in the hippocampus using real-time PCR and ELISA techniques, respectively. In addition, real-time PCR was used to evaluate the mRNA levels of markers associated with neurogenesis (Nestin, DCX, and Ki67) and mitochondrial biogenesis (PGC-1α, NRF-1, and TFAM). The results showed that imipramine, especially at a dose of 20 mg/kg, effectively improved STZ-induced memory impairment. This improvement was associated with an increase in neurogenesis and neurotrophic factors and a decrease in neuroinflammation and mitochondrial biogenesis dysfunction. Based on these results, imipramine appears to be a promising therapeutic option for improving cognitive functions in neurodegenerative diseases such as AD.
Sujet(s)
Maladie d'Alzheimer , Modèles animaux de maladie humaine , Hippocampe , Imipramine , Neurogenèse , Biogenèse des organelles , Rat Wistar , Streptozocine , Animaux , Maladie d'Alzheimer/traitement médicamenteux , Maladie d'Alzheimer/métabolisme , Mâle , Neurogenèse/effets des médicaments et des substances chimiques , Imipramine/pharmacologie , Rats , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Protéine doublecortine , Maladies neuro-inflammatoires/traitement médicamenteux , Mémoire/effets des médicaments et des substances chimiques , Facteur neurotrophique dérivé du cerveau/métabolisme , Troubles de la mémoire/traitement médicamenteux , Neuroprotecteurs/pharmacologie , Antidépresseurs tricycliques/pharmacologie , Facteur neurotrophique dérivé des cellules gliales/métabolisme , Facteur neurotrophique dérivé des cellules gliales/génétique , Cytokines/métabolismeRÉSUMÉ
Postnatal hippocampal neurogenesis is essential for learning and memory. Hippocampal neural precursor cells (NPCs) can be induced to proliferate and differentiate into either glial cells or dentate granule cells. Notably, hippocampal neurogenesis decreases dramatically with age, partly due to a reduction in the NPC pool and a decrease in their proliferative activity. Alpha-melanocyte-stimulating hormone (α-MSH) improves learning, memory, neuronal survival and plasticity. Here, we used postnatally-isolated hippocampal NPCs from Wistar rat pups (male and female combined) to determine the role of the melanocortin analog [Nle4, D-Phe7]-α-MSH (NDP-MSH) in proliferation and fate acquisition of NPCs. Incubation of growth-factor deprived NPCs with 10 nM NDP-MSH for 6 days increased the proportion of Ki-67- and 5-bromo-2'-deoxyuridine (BrdU)-positive cells, compared to the control group, and these effects were blocked by the MC4R antagonist JKC-363. NDP-MSH also increased the proportion of glial fibrillar acidic protein (GFAP)/Ki-67, GFAP/sex-determining region Y-box2 (SOX2) and neuroepithelial stem cell protein (NESTIN)/Ki-67-double positive cells (type-1 and type-2 precursors). Finally, NDP-MSH induced peroxisome proliferator-activated receptor (PPAR)-γ protein expression, and co-incubation with the PPAR-γ inhibitor GW9662 prevented the effect of NDP-MSH on NPC proliferation and differentiation. Our results indicate that in vitro activation of MC4R in growth-factor-deprived postnatal hippocampal NPCs induces proliferation and promotes the relative expansion of the type-1 and type-2 NPC pool through a PPAR-γ-dependent mechanism. These results shed new light on the mechanisms underlying the beneficial effects of melanocortins in hippocampal plasticity and provide evidence linking the MC4R and PPAR-γ pathways in modulation of hippocampal NPC proliferation and differentiation.
Sujet(s)
Différenciation cellulaire , Prolifération cellulaire , Hippocampe , Cellules souches neurales , Neurogenèse , Rat Wistar , Récepteur de la mélanocortine de type 4 , Hormone mélanotrope alpha , Animaux , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Hippocampe/cytologie , Cellules souches neurales/effets des médicaments et des substances chimiques , Cellules souches neurales/métabolisme , Cellules souches neurales/physiologie , Prolifération cellulaire/effets des médicaments et des substances chimiques , Prolifération cellulaire/physiologie , Récepteur de la mélanocortine de type 4/métabolisme , Hormone mélanotrope alpha/pharmacologie , Hormone mélanotrope alpha/analogues et dérivés , Femelle , Différenciation cellulaire/effets des médicaments et des substances chimiques , Différenciation cellulaire/physiologie , Mâle , Neurogenèse/effets des médicaments et des substances chimiques , Neurogenèse/physiologie , Rats , Cellules cultivées , Facteurs de transcription SOX-B1/métabolisme , Animaux nouveau-nés , Protéine gliofibrillaire acide/métabolisme , Récepteur PPAR gamma/métabolismeRÉSUMÉ
Background: Dandouchi polypeptide (DDCP) is derived from Semen Sojae Praeparatum (Dandouchi in Chinese), a fermented product of Glycine max (L.) Merr. Semen Sojae Praeparatum is widely used in the food industry for its unique flavor and nutritional value, and DDCP, as its derivative, also shows potential health benefits in food applications. However, the specific active substances responsible for Semen Sojae Praeparatum and the underlying mechanisms involved have not been fully elucidated. Methods: DDCP was extracted from Semen Sojae Praeparatum using enzymes, and its antidepressant effects were tested in chronic unpredictable mild stress (CUMS)-induced mice. Immunohistochemistry, immunofluorescence, and western blotting were used to analyze neurogenesis and the nuclear factor κB (NF-κB) pathway. Moreover, an adeno-associated virus (AAV) shRNA was used to induce tripartite motif-containing 67 (TRIM67) deficiency to examine the function of TRIM67 in the neuroprotective effects of DDCP in depressive disorders. Results: DDCP reduced depressive behaviors in CUMS mice and the expression of proinflammatory markers in the hippocampus. DDCP promoted neurogenesis and modulated the TRIM67/NF-κB pathway, with TRIM67 deficiency impairing its antidepressant effect. Conclusions: This research revealed that DDCP has a protective effect on countering depression triggered by CUMS. Notably, TRIM67 plays a crucial role in mitigating depression through DDCP, positioning DDCP as a potential therapeutic option for treating depressive disorders.
Sujet(s)
Dépression , Hippocampe , Facteur de transcription NF-kappa B , Neurogenèse , Animaux , Humains , Mâle , Souris , Antidépresseurs/composition chimique , Antidépresseurs/pharmacologie , Antidépresseurs/usage thérapeutique , Comportement animal/effets des médicaments et des substances chimiques , Dépression/métabolisme , Dépression/traitement médicamenteux , Dépression/génétique , Modèles animaux de maladie humaine , Hippocampe/métabolisme , Hippocampe/effets des médicaments et des substances chimiques , Souris de lignée C57BL , Neurogenèse/effets des médicaments et des substances chimiques , Facteur de transcription NF-kappa B/métabolisme , Facteur de transcription NF-kappa B/génétique , Peptides/administration et posologie , Peptides/composition chimique , Peptides/pharmacologie , Peptides/usage thérapeutique , Transduction du signal/effets des médicaments et des substances chimiques , Stress psychologique/traitement médicamenteux , Protéines à motif tripartite/génétique , Protéines à motif tripartite/métabolisme , Ubiquitin-protein ligases/génétique , Ubiquitin-protein ligases/métabolismeRÉSUMÉ
Exercise is known to reduce depression and anxiety symptoms. Although the cellular and molecular mechanisms underlying this effect remain unknown, exercise-induced increases in neurotransmitter release and hippocampal neurogenesis have been hypothesized to play key roles. One neurotransmitter that has been implicated in both antidepressant-like effects and the regulation of hippocampal neurogenesis is serotonin (5-HT). Complete loss of function of the brain 5-HT synthesis enzyme (tryptophan hydroxylase 2, Tph2) has been reported to prevent exercise-induced increases in neurogenesis and to block a subset of antidepressant-like responses to selective serotonin reuptake inhibitors (SSRIs), but whether partial loss of Tph2 function blocks the behavioral and neurogenic effects of exercise has not been established. This study used four tests that are predictive of antidepressant efficacy to determine the impact of 5-HT deficiency on responses to exercise in male and female mice. Our results demonstrate that low 5-HT impairs the behavioral effects of exercise in females in the forced swim and novelty-suppressed feeding tests. However, genetic reductions in 5-HT synthesis did not significantly impact exercise-induced alterations in cellular proliferation or immature neuron production in the hippocampus in either sex. These findings highlight the importance of brain 5-HT in mediating behavioral responses to exercise and suggest that individual differences in brain 5-HT synthesis could influence sensitivity to the mental health benefits of exercise. Furthermore, the observed disconnect between neurogenic and behavioral responses to exercise suggests that increased neurogenesis is unlikely to be the primary driver of the behavioral effects of exercise observed here.